ArticleCell reports2021

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.

Federico Bertoglio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.